Zura Bio Ltd (ZURA)
Zura Bio Ltd is a clinical-stage biotechnology company focused on developing medicines for autoimmune and inflammatory disorders. The company’s pipeline includes Tibulizumab, a bispecific antibody designed to bind and neutralize IL-17A and BAFF in a single molecule, which is being studied in Phase 2 clinical development. Its other programs include Torudokimab (ZB-880), a fully human IgG4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 studies, and Crebankitug (ZB-168), a fully human IgG1 monoclonal antibody targeting interleukin-7 receptor alpha that has also completed Phase 1 studies. Founded in 2022, Zura Bio is headquartered in Henderson, Nevada, and its common stock is listed on the NASDAQ under the symbol ZURA.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ZURA
|
$4.98
|
-8.5% Downside
|
Fair
|
$15.67
|
188.0% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 19, 2026
|
-4.9x
|
2.4x
|
—
|
499.7 M
|
295 M
|
0.0%
|
53.4%
|
24.0
|
—
|
68.5%
|
